IJOYFA Trademark

Trademark Overview

On Friday, October 18, 2024, a trademark application was filed for IJOYFA with the United States Patent and Trademark Office. The USPTO has given the IJOYFA trademark a serial number of 98808697. The federal status of this trademark filing is SUSPENSION LETTER - MAILED as of Thursday, March 27, 2025. This trademark is owned by Gilead Sciences Ireland UC. The IJOYFA trademark is filed in the Pharmaceutical Products category with the following description:

Antiviral pharmaceutical preparations; anti-infective pharmaceutical preparations; anti-fibrotic pharmaceutical preparations; pharmaceutical preparations for treatment and prevention of HIV infection; pharmaceutical preparations for the treatment of liver diseases and disorders; pharmaceutical preparations for the treatment of hematological diseases and disorders; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammatory diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of respiratory and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of kidney and nephropathic diseases and disorders; pharmaceutical preparations for the treatment of arthritis; pharmaceutical preparations for treatment of gastrointestinal diseases and disorders
ijoyfa

General Information

Serial Number98808697
Word MarkIJOYFA
Filing DateFriday, October 18, 2024
Status653 - SUSPENSION LETTER - MAILED
Status DateThursday, March 27, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesAntiviral pharmaceutical preparations; anti-infective pharmaceutical preparations; anti-fibrotic pharmaceutical preparations; pharmaceutical preparations for treatment and prevention of HIV infection; pharmaceutical preparations for the treatment of liver diseases and disorders; pharmaceutical preparations for the treatment of hematological diseases and disorders; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammatory diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of respiratory and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of kidney and nephropathic diseases and disorders; pharmaceutical preparations for the treatment of arthritis; pharmaceutical preparations for treatment of gastrointestinal diseases and disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, October 18, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGilead Sciences Ireland UC
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressCarrigtohill, Co. Cork
IE

Trademark Events

Event DateEvent Description
Friday, October 18, 2024NEW APPLICATION ENTERED
Friday, October 18, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, March 25, 2025ASSIGNED TO EXAMINER
Wednesday, April 2, 2025TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Thursday, March 27, 2025NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, March 27, 2025LETTER OF SUSPENSION E-MAILED
Thursday, March 27, 2025SUSPENSION LETTER WRITTEN

Related Keywords

ijoyfa preparations pharmaceutical treatment disorders diseases anti respiratory autoimmune pulmonary kidney